Innovation Efforts Offer A Way To Change FDA's Views On Risk, Industry Says
This article was originally published in The Gray Sheet
Executive Summary
FDA should put more emphasis on product benefits and patients' willingness to take on risk in pre-market reviews of particularly innovative devices, industry participants argued during an agency workshop last week.
You may also be interested in...
Risk-Benefit Guidance Aims To Improve Pre-Market Review Predictability
It takes more than safety and effectiveness data alone for FDA device reviewers to determine how benefits stack up against risks in a pre-market submission, the agency accentuates in new draft guidance.
Risk-Benefit Guidance Aims To Improve Pre-Market Review Predictability
It takes more than safety and effectiveness data alone for FDA device reviewers to determine how benefits stack up against risks in a pre-market submission, the agency accentuates in new draft guidance.
Shuren: New Clinical Trial Guidelines In The Works
FDA device center director Jeffrey Shuren says new guidance documents coming down the pike will clarify issues related to clinical trial design and approval.